The COVID-19 pandemic demonstrated that the mass production of vaccines is crucial for our healthcare system. In order to ...

Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX-201 to treat osteoarthritis of the knee: Brisbane, California Saturday, April 5, 2 ...

Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, 'P134 Cell Injection,' which has received Investigational New Drug (IND) ...

Pacira Biosciences leads in non-opioid pain relief with Exparel & upcoming knee osteoarthritis therapy. Click here to read my ...

Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...

Q4 2024 Earnings Conference Call April 9, 2025 8:00 AM ET. Company Participants. Frank Mathias - Chief Executive Officer Sebastien Ribault - Chi ...

The death of a 16-year-old boy taking a gene therapy this month dealt a fresh blow to the Duchenne muscular dystrophy community. The patient died from acute liver failure months after starting ...

The agreement relates to the GMP manufacture of the vaccine candidate codenamed AZD1222, which is based on an adenovirus vector and recently entered clinical trials at several sites in the UK.

New conditionally replicative adenovirus vector with synNotch receptor gene for MIBC treatment March 25, 2025 The MIBC subtype accounts for around 25% of all BC cases, with a significant proportion of ...